514 filings
Page 7 of 26
8-K
og8z046sjsz1 f6
11 Apr 17
ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
12:00am
8-K
kzvqr
10 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
vhahwahz7
27 Mar 17
ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
12:00am
8-K
e633aw
7 Mar 17
ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
12:00am
8-K
mi1417 6us5z5hno
17 Feb 17
Other Events
12:00am
8-K
0bl4sf 38d162cqb
10 Jan 17
Entry into a Material Definitive Agreement
12:00am
8-K
k46vdk3qq wv
7 Nov 16
Arqule Reports Third Quarter 2016 Financial Results
12:00am
8-K
d7xye6ak
26 Oct 16
Entry into a Material Definitive Agreement
12:00am
424B5
pvau54ufhydyc vbn83
26 Oct 16
Prospectus supplement for primary offering
12:00am
EFFECT
0rh3j7dbhucdpz0z769
5 Oct 16
Notice of effectiveness
12:00am
CORRESP
iq3g6r
3 Oct 16
Correspondence with SEC
12:00am
CORRESP
s0a3qoc5xgkuzqbt6
23 Sep 16
Correspondence with SEC
12:00am
UPLOAD
ibz1p
15 Sep 16
Letter from SEC
12:00am
8-K
w8rvg wjif1e7dovhi
3 Aug 16
Arqule Reports Second Quarter 2016 Financial Results
12:00am